Pharma BD Deal Intelligence

Valeant Pharmaceuticals International, Inc. / Dermik Laboratories (Sanofi dermatology unit)

2011 · Asset Purchase · $425M · Complete

Announcement Sentiment

Positive

Sanofi divested its US/Canada dermatology unit Dermik to Valeant for ~$425M cash. Portfolio included Sculptra, BenzaClin, Carac. Closed December 16, 2011 with FTC-mandated divestitures.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Pipeline outcome

Mixed

Assessment window: 10yr post-close.

Key facts

Announced Jul 11, 2011
Closed Dec 16, 2011
Deal value $425M
Deal type Asset Purchase
Therapeutic area Aesthetic dermatology, acne, actinic keratosis
Indications Aesthetic dermatology, acne, actinic keratosis
Key assets Sculptra, BenzaClin, Carac dermatology portfolio
Mechanism Topical/injectable dermatology agents (poly-L-lactic acid, clindamycin/BPO, fluorouracil)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals